{
    "clinical_study": {
        "@rank": "14926", 
        "arm_group": {
            "arm_group_label": "tacrolimus + biological agents"
        }, 
        "brief_summary": {
            "textblock": "This study is to evaluate  the safety and the effectiveness  of treatment  with tacrolimus\n      and biological agents."
        }, 
        "brief_title": "Special Drug Use-Results Survey of Prograf Capsule in Rheumatoid Arthritis Patients", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to confirm the safety of 24 weeks-treatment with the\n      combination of tacrolimus + biological agents, and to assess the efficacy using SDAI, CDAI,\n      DAS28-CRP, MMP-3, MHAQ  in patients with rheumatoid arthritis who have not achieved SDAI\n      remission despite of using biological agents for over 8 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with rheumatoid arthritis who have been treated with biological agents over\n             8 weeks but have not achieved SDAI remission (SDAI  < 3.3)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with rheumatoid arthritis who have been treated with biological agents"
            }
        }, 
        "enrollment": {
            "#text": "1200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01870908", 
            "org_study_id": "PRGR03"
        }, 
        "intervention": [
            {
                "arm_group_label": "tacrolimus + biological agents", 
                "intervention_name": "tacrolimus", 
                "intervention_type": "Drug", 
                "other_name": "prograf"
            }, 
            {
                "arm_group_label": "tacrolimus + biological agents", 
                "intervention_name": "biological agents", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tacrolimus"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 4, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kantou", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shikoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Touhoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Drug Use-result Survey to Assess the Safety and Efficacy of the Combination of Tacrolimus + Biological Agents in Daily Clinical Settings", 
        "overall_contact": {
            "email": "clinicaltrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Use Central Contact", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Simplified disease activity index (SDAI)", 
            "safety_issue": "No", 
            "time_frame": "Baseline and week-24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01870908"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical disease activity index (CDAI)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, week-12 and week-24"
            }, 
            {
                "measure": "Disease Activity Score 28 (DAS28)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, week-12 and week-24"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}